Curated News
By: NewsRamp Editorial Staff
September 29, 2026

VERAXA Advances VXA-222 Bispecific ADC, Files Key Patents

Discuss on Substack
Original Source

TLDR

  • VERAXA advances VXA-222 ADC beyond discovery, targeting two antigens to boost cancer selectivity and strengthen its oncology pipeline.
  • VXA-222 uses an AND-gate bispecific design to bind two tumor antigens, with engineering, linkers, and conjugation now moving into preclinical studies.
  • VERAXA's progress on targeted cancer therapies could lead to more precise treatments and better outcomes for patients worldwide.
  • VERAXA's VXA-222 ADC employs click chemistry and an AND-gate design to recognize two tumor antigens simultaneously.

Impact - Why it Matters

This news matters because it demonstrates VERAXA's progress in developing next-generation antibody-based therapeutics that could overcome limitations of current cancer treatments. The AND-gate design of VXA-222 may enhance tumor selectivity, potentially reducing side effects and improving patient outcomes. The patent filings strengthen VERAXA's intellectual property position, which is crucial for attracting investment and partnerships in the competitive biotech landscape. As the company moves toward clinical development, success could lead to innovative therapies for cancer patients and create value for shareholders. Moreover, the involvement of InvestorWire highlights the importance of effective communication in reaching investors and the public, ensuring that stakeholders are informed about promising developments in the life sciences sector.

Summary

VERAXA Biotech (NASDAQ: VRXA), a company building a premier engine for next-generation antibody-based therapeutics, has advanced its VXA-222 bispecific antibody-drug conjugate (ADC) program beyond the initial discovery phase. This milestone follows the completion of its collaboration with OmniAb and paves the way for the company to engineer the final candidate using its proprietary antibody-engineering, linker, and conjugation technologies. The next steps include conducting in vitro and in vivo preclinical studies. VXA-222 utilizes an innovative “AND-gate” design that aims to recognize two tumor-associated antigens simultaneously, potentially increasing selectivity for cancer cells while sparing healthy tissue. This approach could lead to more effective and safer cancer treatments. VERAXA continues to develop a broader oncology pipeline that spans ADCs, T-cell engagers, and other engineered antibody formats. In addition to its scientific progress, VERAXA has filed its first patents covering its BiTAC-TCE and BiTAC-ADC platforms, as well as related payload, click-chemistry, and conjugation technologies. These filings add to an intellectual-property portfolio that already includes more than 50 granted patents across 26 families in 14 countries, underscoring the company’s commitment to protecting its innovations.

For more details, visit https://ibn.fm/S3tyP. The full article is available through InvestorWire, a specialized communications platform with a focus on advanced wire-grade press release syndication. InvestorWire is part of the Dynamic Brand Portfolio @ IBN, which delivers access to a vast network of wire solutions, editorial syndication to 5,000+ outlets, press release enhancement, social media distribution, and tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, InvestorWire is uniquely positioned to serve private and public companies seeking to reach a wide audience of investors, influencers, consumers, journalists, and the general public. For more information, please visit https://www.InvestorWire.com.

VERAXA Biotech was founded on scientific breakthroughs made at the European Molecular Biology Laboratory, a world-renowned institution known for pioneering life science research. The company is guided by rigorous quality-by-design principles and is rapidly advancing its pipeline of ADCs and proprietary BiTAC formats into clinical development and beyond. For regular updates, visit www.VERAXA.com. Investors can also find the latest news and updates relating to VRXA in the company’s newsroom at https://ibn.fm/VRXA.

Source Statement

This curated news summary relied on content distributed by InvestorBrandNetwork (IBN). Read the original source here, VERAXA Advances VXA-222 Bispecific ADC, Files Key Patents

Blockchain registration record for this content